Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. [electronic resource]
Producer: 20140220Description: 24-32 p. digitalISSN:- 1872-7980
- Animals
- Antineoplastic Agents -- pharmacology
- Carcinoma
- Cell Cycle
- Cell Line, Tumor
- Cell Survival
- Cisplatin -- pharmacology
- Enzyme Activation
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Imidazoles -- pharmacology
- Inhibitory Concentration 50
- MAP Kinase Signaling System
- Mice
- Mice, Nude
- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms -- genetics
- Neoplasm Transplantation
- Paclitaxel -- pharmacology
- Phosphatidylinositol 3-Kinases -- metabolism
- Phosphoinositide-3 Kinase Inhibitors
- Quinolines -- pharmacology
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.